Bennett SN, McNeil MM, Bland LA, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med 1995; 333: 147–54.
Carr S, Waterman S, Rutherford G, et al. Postsurgical infections associated with an extrinsically contaminated intravenous anesthetic agent-California, Illinois, Maine, and Michigan. MMWR 1990; 39: 426–33.
Bach A, Motsch J. Infectious risks associated with the use of propofol. Acta Anaesthesiol Scand 1996; 40: 1189–96.
McNeil MM, Lasker BA, Lott TJ, Jarvis WR. Postsurgical Candida albicans infections associated with an extrinsically contaminated intravenous anesthetic agent. J Clin Microbiol 1999; 37: 1398–403.
Veber B, Gachot B, Bedos JP, Wolff M. Severe sepsis after intravenous injection of contaminated propofol (Letter). Anesthesiology 1994; 80: 712–3.
Arduino MJ, Bland LA, McAllister SK, et al. Microbial growth and endotoxin production in the intravenous anesthetic propofol. Infect Control Hosp Epidemiol 1991; 12: 535–9.
Kuehnert MJ, Webb RM, Jochimsen EM, et al. Staphylococcus aureus bloodstream infections among patients undergoing electroconvulsive therapy traced to breaks in infection control and possible extrinsic contamination by propofol. Anesth Analg 1997; 85: 420–5.
Berry CB, Gillespie T, Hood J, Scott NB. Growth of micro-organisms in solutions of intravenous anaesthetic agents. Anaesthesia 1993; 48: 30–2.
Sosis MB, Braverman B, Villaflor E. Propofol, but not thiopental, supports the growth of Candida albicans. Anesth Analg 1995; 81: 132–4.
Sosis MB, Braverman B. Growth of Staphylococcus aureus in four intravenous anesthetics. Anesth Analg 1993; 77: 766–8.
Tessler M, Dascal A, Gioseffini S, Miller M, Mendelson J. Growth curves of Staphylococcus aureus, Candida albicans, and Moraxella osloensis in propofol and other media. Can J Anaesth 1992; 39: 509–11.
Daily MJ, Dickey JB, Packo KH. Endogenous Candida endophthalmitis after intravenous anesthesia with propofol. Arch Ophthalmol 1991; 109: 1081–4.
Graystone S, Wells MF, Earrell DJ. Do intensive care drug infusions support microbial growth? Anaesth Intensive Care 1997; 25: 640–2.
Farrington M, McGinnes J, Matthews I, Park GR. Do infusions of midazolam and propofol pose an infection risk to critically ill patients? Br J Anaesth 1994; 72: 415–7.
Crowther J, Hrazdil J, Jolly DE, Galbraith JC, Greacen M, Grace M. Growth of microorganisms in propofol, thiopental, and a 1:1 mixture of propofol and thiopental. Anesth Analg 1996; 82: 475–8.
Gajraj RJ, Hodson MJ, Gillespie JA, Kenny GNC, Scott NB. Antibacterial activity of lidocaine in mixtures with Diprivan. Br J Anaesth 1998; 81: 444–8.
Wachowski I, Jolly DE, Hrazdil J, Galbraith JC, Greacen M, Clanachan AS. The growth of microorganisms in propofol and mixtures of propofol and lidocaine. Anesth Analg 1999; 88: 209–12.
Vidovich MI, Peterson LR, Wong HT. The effect of lidocaine on bacterial growth in propofol. Anesth Analg 1999; 88: 936–8.
Sakuragi T, Yanagisawa K, Shirai Y, Dan K. Growth of Escherichia coli in propofol, lidocaine, and mixtures of propofol and lidocaine. Acta Anaesthesiol Scand 1999; 43: 476–9.
Hart B. ‘Diprivan’: a change of formulation (Letter). Eur J Anaesthesiol 2000; 17: 71–3.
Culver DH, Horan EC, Gaynes RP, et al., National Nosocomial Infections Surveillance System. Surgical wound infection rates by wound class, operative procedure, and patient risk index. Am J Med 1991; 91(suppl 3B): 152S-7S.
Haley RW, Culver DH, Morgan WM, White JW, Emori EG, Hooton EM. Identifying patients at high risk of surgical wound infection. A simple multivariate index of patient susceptibility and wound contamination. Am J Epidemiol 1985; 121: 206–15.
Haley RW, Culver DH, White JW, Morgan WM, Emori TG. The nationwide nosocomial infection rate. A new need for vital statistics. Am J Epidemiol 1985; 121: 159–67.
Nichols RL, Smith JW. Bacterial contamination of an anesthetic agent (Editorial). N Engl J Med 1995; 333: 184–5.
Hughes S. American Society of Anesthesiologists (ASA): Recommendations for Infection Control for the Practice of Anesthesiology, (2nd ed.). http://www.asahq.org/ProfInfo/Infection/Infection_ TOC.html 2001.
Pearson ML. Centers for Disease Control (CDC): Guideline for prevention of intravascular device-related infections. Part 1. Intravascular device-related infections: an overview. The Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1996; 24: 262–77.
Zacher AN, Zornow MH, Evans G. Drug contamination from opening glass ampules. Anesthesiology 1991; 75: 893–5.
Kempen PM, Sulkowski E, Sawyer SA. Glass ampules and associated hazards. Crit Care Med 1989; 17: 812–3.
Rosenberg AD, Bernstein DB, Bernstein RL, Skovron ML, Ramanathan S, Turndorf H. Accidental needlesticks: do anesthesiologists practice proper infection control precautions? Am J Anesthesiol 1995; 22: 125–32.
Lessard MR, Trépanier CA, Gourdeau M, Denault PH. A microbiological study of the contamination of the syringes used in anaesthesia practice. Can J Anaesth 1988; 35: 567–9.
Magee L, Godsiff L, Matthews I, Farrington M, Park GR. Anaesthetic drugs and bacterial contamination. Eur J Anaesthesiol 1995; 12(Suppl. 12): 41–3.
Warwick JP, Blake D. Drawing up propofol (Letter). Anaesthesia 1994; 49: 172.
McLeod GA, Pace N, Inglis MD. Bacterial growth in propofol (Letter). Br J Anaesthesia 1991; 67: 665–6.
Downs GJ, Haley PR, Parent JB. Propofol: can a single ampule be used for multiple patients? (Letter). Anesthesiology 1991; 74: 1156–7.
Bach A, Motsch J, Schmidt H, et al. In-use contamination of propofol. A clinical study. Eur J Anaesthesiol 1997; 14: 178–83.
McHugh GJ, Roper GM. Propofol emulsion and bacterial contamination. Can J Anaesth 1995; 42: 801–4.
Webb SAR, Roberts B, Breheny FX, Golledge CL, Cameron PD, Van Heerden PV. Contamination of propofol infusions in the intensive care unit: incidence and clinical significance. Anaesth Intensive Care 1998; 26: 162–4.